Lucio Ildebrando Cocco

List of Publications by Year in Descending Order

233 papers	9,036 citations	49 h-index	85 g-index
257 ext. papers	10,089 ext. citations	5.1 avg, IF	5.54 L-index

#	Paper	IF	Citations
233	The wide and growing range of lamin B-related diseases: from laminopathies to cancer.. *Cellular and Molecular Life Sciences*, **2022**, 79, 126	10.3	3
232	Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53.. *Cells*, **2022**, 11,	7.9	1
231	Impact of phospholipase C 1 in glioblastoma: a study on the main mechanisms of tumor aggressiveness.. *Cellular and Molecular Life Sciences*, **2022**, 79, 195	10.3	0
230	Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.. *Aging*, **2022**, 14, 3365-3386	5.6	0
229	Role of PLC1 in the modulation of cell migration and cell invasion in glioblastoma. *Advances in Biological Regulation*, **2021**, 100838	6.2	1
228	Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53. *Advances in Biological Regulation*, **2021**, 100840	6.2	0
227	Prediction of genetic alteration of phospholipase C isozymes in brain disorders: Studies with deep learning. *Advances in Biological Regulation*, **2021**, 82, 100833	6.2	1
226	GSK-3Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. *Cells*, **2021**, 10,	7.9	7
225	"Modulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemia". *Frontiers in Oncology*, **2021**, 11, 678824	5.3	2
224	How Inflammation Pathways Contribute to Cell Death in Neuro-Muscular Disorders. *Biomolecules*, **2021**, 11,	5.9	2
223	Cell signaling pathways in autosomal-dominant leukodystrophy(ADLD): the intriguing role of the astrocytes. *Cellular and Molecular Life Sciences*, **2021**, 78, 2781-2795	10.3	2
222	Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53. *Advances in Biological Regulation*, **2021**, 79, 100780	6.2	3
221	Clinical and Molecular Insights in Erythropoiesis Regulation of Signal Transduction Pathways in Myelodysplastic Syndromes and Thalassemia. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	3
220	Lamin B1 Accumulation Effects on Autosomal Dominant Leukodystrophy (ADLD): Induction of Reactivity in the Astrocytes. *Cells*, **2021**, 10,	7.9	1
219	The Italian law on body donation: A position paper of the Italian College of Anatomists. *Annals of Anatomy*, **2021**, 238, 151761	2.9	1
218	Location-dependent role of phospholipase C signaling in the brain: Physiology and pathology. *Advances in Biological Regulation*, **2021**, 79, 100771	6.2	4
217	Near-Peer Teaching in Human Anatomy from a Tutors Perspective: An Eighteen-Year-Old Experience at the University of Bologna.. *International Journal of Environmental Research and Public Health*, **2021**, 19,	4.6	1

216	Targeting GSK3 and Associated Signaling Pathways Involved in Cancer. *Cells*, **2020**, 9,	7.9	67
215	Nuclear Inositides and Inositide-Dependent Signaling Pathways in Myelodysplastic Syndromes. *Cells* , **2020**, 9,	7.9	7
214	Phosphoinositide-Dependent Signaling in Cancer: A Focus on Phospholipase C Isozymes. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	17
213	Sequential Analysis of miRNA Profiling during Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes. *Blood*, **2020**, 136, 6-7	2.2	
212	Azacitidine and Lenalidomide in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study and Impact of Cytogenetic Scores and Mutational Status on Long-Lasting Responses. *Blood*, **2020**, 136, 45-45	2.2	
211	Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines. *Aging*, **2020**, 12, 10194-10210	5.6	11
210	Recent advances in MDS mutation landscape: Splicing and signalling. *Advances in Biological Regulation*, **2020**, 75, 100673	6.2	4
209	The function of PLC□1 in developing mouse mDA system. *Advances in Biological Regulation*, **2020**, 75, 100654	6.2	4
208	Abilities of □Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells. *Advances in Biological Regulation*, **2020**, 75, 100672	6.2	7
207	Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling. *Advances in Biological Regulation*, **2020**, 78, 100758	6.2	9
206	Subcellular Localization Relevance and Cancer-Associated Mechanisms of Diacylglycerol Kinases. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	3
205	Cancer therapy and treatments during COVID-19 era. *Advances in Biological Regulation*, **2020**, 77, 100739	6.2	19
204	Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS). *FASEB Journal*, **2020**, 34, 15400-15416	0.9	1
203	Inositide-Dependent Nuclear Signalling in Health and Disease. *Handbook of Experimental Pharmacology*, **2020**, 259, 291-308	3.2	2
202	AKT-dependent phosphorylation of the adenosine deaminases ADAR-1 and -2 inhibits deaminase activity. *FASEB Journal*, **2019**, 33, 9044-9061	0.9	13
201	Phosphoinositide 3 Kinase Signaling in Human Stem Cells from Reprogramming to Differentiation: A Tale in Cytoplasmic and Nuclear Compartments. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	13
200	Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals. *Advances in Biological Regulation*, **2019**, 72, 22-40	6.2	7
199	Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes. *Leukemia*, **2019**, 33, 2276-2290	10.7	17

198	Phospholipase C-1 potentiates glucose-stimulated insulin secretion. *FASEB Journal*, **2019**, 33, 10668-10679	6.9	9
197	Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit. *Journal of Cellular Physiology*, **2019**, 234, 11188-11199	7	14
196	Phospholipase C-1 interacts with cyclin E in adipose- derived stem cells osteogenic differentiation. *Advances in Biological Regulation*, **2019**, 71, 1-9	6.2	12
195	Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. *Advances in Biological Regulation*, **2019**, 71, 172-182	6.2	25
194	Therapeutic potential of nvp-bkm120 in human osteosarcomas cells. *Journal of Cellular Physiology*, **2019**, 234, 10907-10917	7	8
193	Nuclear phospholipase C isoenzyme imbalance leads to pathologies in brain, hematologic, neuromuscular, and fertility disorders. *Journal of Lipid Research*, **2019**, 60, 312-317	6.3	16
192	The regulation of insulin secretion via phosphoinositide-specific phospholipase C signaling. *Advances in Biological Regulation*, **2019**, 71, 10-18	6.2	7
191	Metformin influences drug sensitivity in pancreatic cancer cells. *Advances in Biological Regulation*, **2018**, 68, 13-30	6.2	34
190	Communication between median and musculocutaneous nerve at the level of cubital fossa - A case report. *Translational Research in Anatomy*, **2018**, 11, 1-4	0.8	
189	Current therapy and new drugs: a road to personalized treatment of myelodysplastic syndromes. *Expert Review of Precision Medicine and Drug Development*, **2018**, 3, 23-31	1.6	1
188	Nuclear translocation of PKC- is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs). *FASEB Journal*, **2018**, 32, 681-692	0.9	16
187	Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cells-Power of nutraceuticals. *Advances in Biological Regulation*, **2018**, 67, 190-211	6.2	21
186	Roles of p53, NF-B and the androgen receptor in controlling NGAL expression in prostate cancer cell lines. *Advances in Biological Regulation*, **2018**, 69, 43-62	6.2	16
185	Comparison of Two Different Therapeutic Regimens with Azacitidine and Lenalidomide (Combined versus Sequential) in Higher-Risk Myelodysplastic Syndromes. Update of Long-Term Results of a Randomized Phase II Multicenter Study. *Blood*, **2018**, 132, 4365-4365	2.2	1
184	Negative Prognostic Relevance of a Specific 3-Gene Cluster in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy. *Blood*, **2018**, 132, 4347-4347	2.2	
183	Nuclear inositide signaling and cell cycle. *Advances in Biological Regulation*, **2018**, 67, 1-6	6.2	25
182	PLC1: Potential arbitrator of cancer progression. *Advances in Biological Regulation*, **2018**, 67, 179-189	6.2	28
181	Netrin-1/DCC-mediated PLC1 activation is required for axon guidance and brain structure development. *EMBO Reports*, **2018**, 19,	6.5	16

180	Endoscopic endonasal approach to primitive Meckel's cave tumors: a clinical series. *Acta Neurochirurgica*, **2018**, 160, 2349-2361	3	8
179	Zafirlukast promotes insulin secretion by increasing calcium influx through L-type calcium channels. *Journal of Cellular Physiology*, **2018**, 233, 8701-8710	7	7
178	Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. *Advances in Biological Regulation*, **2018**, 69, 16-34	6.2	20
177	Nuclear Inositide Signaling Via Phospholipase C. *Journal of Cellular Biochemistry*, **2017**, 118, 1969-1978	4.7	22
176	PLC-β1 and cell differentiation: An insight into myogenesis and osteogenesis. *Advances in Biological Regulation*, **2017**, 63, 1-5	6.2	27
175	Forebrain-specific ablation of phospholipase Cβ1 causes manic-like behavior. *Molecular Psychiatry*, **2017**, 22, 1473-1482	15.1	33
174	Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases. *Advances in Biological Regulation*, **2017**, 65, 77-88	6.2	31
173	Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. *Aging*, **2017**, 9, 1477-1536	5.6	112
172	Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. *Oncotarget*, **2017**, 8, 14221-14250	3.3	68
171	Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis. *Journal of Cellular Biochemistry*, **2017**, 118, 819-828	4.7	36
170	Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis. *Advances in Biological Regulation*, **2017**, 63, 32-48	6.2	28
169	Nuclear Localization of Diacylglycerol Kinase Alpha in K562 Cells Is Involved in Cell Cycle Progression. *Journal of Cellular Physiology*, **2017**, 232, 2550-2557	7	22
168	Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells. *Oncotarget*, **2017**, 8, 76525-76557	3.3	15
167	Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression. *Oncotarget*, **2017**, 8, 113013-113033	3.3	8
166	Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2016**, 1863, 438-448	4.9	56
165	Nuclear translocation of PKCβ isoenzyme is involved in neurogenic commitment of human neural crest-derived periodontal ligament stem cells. *Cellular Signalling*, **2016**, 28, 1631-41	4.9	37
164	Quantitative profiling of the endonuclear glycerophospholipidome of murine embryonic fibroblasts. *Journal of Lipid Research*, **2016**, 57, 1492-506	6.3	9
163	Nuclear Phosphatidylinositol Signaling: Focus on Phosphatidylinositol Phosphate Kinases and Phospholipases C. *Journal of Cellular Physiology*, **2016**, 231, 1645-55	7	24

162	The therapeutic potential of mTOR inhibitors in breast cancer. *British Journal of Clinical Pharmacology*, **2016**, 82, 1189-1212	3.8	72
161	Modulation of nuclear PI-PLCbeta1 during cell differentiation. *Advances in Biological Regulation*, **2016**, 60, 1-5	6.2	19
160	Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes. *Expert Opinion on Therapeutic Targets*, **2016**, 20, 677-87	6.4	12
159	Primary phospholipase C and brain disorders. *Advances in Biological Regulation*, **2016**, 61, 80-5	6.2	54
158	Novel roles of androgen receptor, epidermal growth factor receptor, TP53, regulatory RNAs, NF-kappa-B, chromosomal translocations, neutrophil associated gelatinase, and matrix metalloproteinase-9 in prostate cancer and prostate cancer stem cells. *Advances in Biological Regulation*, **2016**, 60, 64-87	6.2	26
157	IPMK and □catenin mediate PLC-□-dependent signaling in myogenic differentiation. *Oncotarget*, **2016**, 7, 84118-84127	3.3	6
156	Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling. *Oncotarget*, **2016**, 7, 5521-37	3.3	27
155	Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation. *Current Pharmaceutical Design*, **2016**, 22, 2345-8	3.3	18
154	Molecular Mechanisms Underlying Psychological Stress and Cancer. *Current Pharmaceutical Design*, **2016**, 22, 2389-402	3.3	54
153	Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy. *Current Pharmaceutical Design*, **2016**, 22, 2358-88	3.3	30
152	Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes. *Current Pharmaceutical Design*, **2016**, 22, 2349-57	3.3	12
151	Role of Nuclear Inositide Signalling and microRNA Signature in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy. *Blood*, **2016**, 128, 5091-5091	2.2	
150	Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study. *Blood*, **2016**, 128, 3169-3169	2.2	
149	BMP-2 Induced Expression of PLC□ That is a Positive Regulator of Osteoblast Differentiation. *Journal of Cellular Physiology*, **2016**, 231, 623-9	7	22
148	Endoscopic endonasal anatomy of the ophthalmic artery in the optic canal. *Acta Neurochirurgica*, **2016**, 158, 1343-50	3	9
147	Effects of mutations in Wnt/□catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2016**, 1863, 2942-2976	4.9	101
146	Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. *Advances in Biological Regulation*, **2015**, 59, 65-81	6.2	98
145	Foreword: "The PI3-kinase/Akt pathway: From signaling to diseases". *Advances in Biological Regulation*, **2015**, 59, 1-3	6.2	9

144	An increased expression of PI-PLC1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes. *Journal of Leukocyte Biology*, **2015**, 98, 769-80	6.5	22
143	PLC1a and PLC1b selective regulation and cyclin D3 modulation reduced by kinamycin F during k562 cell differentiation. *Journal of Cellular Physiology*, **2015**, 230, 587-94	7	7
142	Phosphoinositide-specific phospholipase C in health and disease. *Journal of Lipid Research*, **2015**, 56, 1853-60	6.3	83
141	PLC and PI3K/Akt/mTOR signalling in disease and cancer. *Advances in Biological Regulation*, **2015**, 57, 10-6	6.2	95
140	Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis. *Advances in Biological Regulation*, **2015**, 57, 75-101	6.2	76
139	PI-PLC1b affects Akt activation, cyclin E expression, and caspase cleavage, promoting cell survival in pro-B-lymphoblastic cells exposed to oxidative stress. *FASEB Journal*, **2015**, 29, 1383-94	0.9	8
138	Quantitative phosphoproteome analysis of embryonic stem cell differentiation toward blood. *Oncotarget*, **2015**, 6, 10924-39	3.3	6
137	Elevated O-GlcNAcylation promotes colonic inflammation and tumorigenesis by modulating NF-B signaling. *Oncotarget*, **2015**, 6, 12529-42	3.3	56
136	Association of Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes. Final Results of a Randomized Phase II Multicenter Study. *Blood*, **2015**, 126, 2871-2871	2.2	1
135	Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy. *Advances in Biological Regulation*, **2014**, 54, 176-96	6.2	64
134	Identification of the PKR nuclear interactome reveals roles in ribosome biogenesis, mRNA processing and cell division. *Journal of Cellular Physiology*, **2014**, 229, 1047-60	7	14
133	Protein kinase C involvement in cell cycle modulation. *Biochemical Society Transactions*, **2014**, 42, 1471-65.1		45
132	Nuclear PI-PLC1: an appraisal on targets and pathology. *Advances in Biological Regulation*, **2014**, 54, 2-11	6.2	28
131	Targeting breast cancer initiating cells: advances in breast cancer research and therapy. *Advances in Biological Regulation*, **2014**, 56, 81-107	6.2	28
130	Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. *Oncotarget*, **2014**, 5, 4603-50	3.3	179
129	GSK-3 as potential target for therapeutic intervention in cancer. *Oncotarget*, **2014**, 5, 2881-911	3.3	332
128	Prohibitin 2 represents a novel nuclear AKT substrate during all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells. *FASEB Journal*, **2014**, 28, 2009-19	0.9	22
127	Addition of Lenalidomide (LEN) to Azacitidine (AZA) (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes (MDS): A Randomized Phase II Multicenter Study. *Blood*, **2014** , 124, 4648-4648	2.2	3

126	PLC-beta 1 regulates the expression of miR-210 during mithramycin-mediated erythroid differentiation in K562 cells. *Oncotarget*, **2014**, 5, 4222-31	3.3	18
125	A novel DAG-dependent mechanism links PKC? and Cyclin B1 regulating cell cycle progression. *Oncotarget*, **2014**, 5, 11526-40	3.3	16
124	Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy. *Mini-Reviews in Medicinal Chemistry*, **2014**, 14, 873-883	3.2	17
123	Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy. *Mini-Reviews in Medicinal Chemistry*, **2014**,	3.2	8
122	The physiological roles of primary phospholipase C. *Advances in Biological Regulation*, **2013**, 53, 232-41	6.2	70
121	Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. *Critical Reviews in Oncology/Hematology*, **2013**, 88, 231-45	7	23
120	Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. *Advances in Biological Regulation*, **2013**, 53, 146-55	6.2	14
119	The protein kinase Akt/PKB regulates both prelamin A degradation and Lmna gene expression. *FASEB Journal*, **2013**, 27, 2145-55	0.9	59
118	K562 cell proliferation is modulated by PLC1 through a PKC-mediated pathway. *Cell Cycle*, **2013**, 12, 1713-21	4.7	23
117	Phosphoinositide-specific phospholipase C 1 b (PI-PLC1b) interactome: affinity purification-mass spectrometry analysis of PI-PLC1b with nuclear protein. *Molecular and Cellular Proteomics*, **2013**, 12, 2220-35	7.6	16
116	Nuclear phospholipase C 1 signaling, epigenetics and treatments in MDS. *Advances in Biological Regulation*, **2013**, 53, 2-7	6.2	29
115	Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes. *Clinical Cancer Research*, **2013**, 19, 3297-308	12.9	50
114	Nuclear inositide specific phospholipase C signalling: interactions and activity. *FEBS Journal*, **2013**, 280, 6311-21	5.7	28
113	Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q). *Blood*, **2013**, 122, 5227-5227	2.2	
112	Revisiting nuclear phospholipase C signalling in MDS. *Advances in Biological Regulation*, **2012**, 52, 2-6	6.2	20
111	The emerging multiple roles of nuclear Akt. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2012**, 1823, 2168-78	4.9	134
110	Targeting the cancer initiating cell: the ultimate target for cancer therapy. *Current Pharmaceutical Design*, **2012**, 18, 1784-95	3.3	36
109	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. *Oncotarget*, **2012**, 3, 1068-111	3.3	250

108	Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. *Oncotarget*, **2012**, 3, 954-87	3.3	214
107	PI-PLC□ gene copy number alterations in breast cancer. *Oncology Reports*, **2012**, 27, 403-8	3.5	7
106	Nuclear PLCs affect insulin secretion by targeting PPAR□in pancreatic □cells. *FASEB Journal*, **2012**, 26, 203-10	0.9	25
105	A role for PLC□ in myotonic dystrophies type 1 and 2. *FASEB Journal*, **2012**, 26, 3042-8	0.9	20
104	Nuclear PI-PLC□ and myelodysplastic syndromes: genetics and epigenetics. *Current Pharmaceutical Design*, **2012**, 18, 1751-4	3.3	8
103	Advances in targeting signal transduction pathways. *Oncotarget*, **2012**, 3, 1505-21	3.3	39
102	Nuclear phosphoinositides: location, regulation and function. *Sub-Cellular Biochemistry*, **2012**, 59, 335-61	5.5	27
101	Nuclear PI-PLC □ and Myelodysplastic syndromes: from bench to clinics. *Current Topics in Microbiology and Immunology*, **2012**, 362, 235-45	3.3	7
100	Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients. *Blood*, **2012**, 120, 1289-1289	2.2	
99	Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients. *Blood*, **2012**, 120, 4951-4951	2.2	
98	Physiology and pathology of nuclear phospholipase C □. *Advances in Enzyme Regulation*, **2011**, 51, 2-12		16
97	Reverse-phase protein microarrays (RPPA) as a diagnostic and therapeutic guide in multidrug resistant leukemia. *International Journal of Oncology*, **2011**, 38, 427-35	4.4	10
96	The physiology and pathology of inositide signaling in the nucleus. *Journal of Cellular Physiology*, **2011**, 226, 14-20	7	26
95	Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. *Journal of Cellular Physiology*, **2011**, 226, 822-31	7	52
94	Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. *Journal of Cellular Physiology*, **2011**, 226, 2762-81	7	124
93	Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. *Cell Cycle*, **2011**, 10, 3003-15	4.7	71
92	Ankrd2/ARPP is a novel Akt2 specific substrate and regulates myogenic differentiation upon cellular exposure to H(2)O(2). *Molecular Biology of the Cell*, **2011**, 22, 2946-56	3.5	39
91	Nuclear phosphoinositides and their roles in cell biology and disease. *Critical Reviews in Biochemistry and Molecular Biology*, **2011**, 46, 436-57	8.7	28

90	Nuclear phospholipase C in biological control and cancer. *Critical Reviews in Eukaryotic Gene Expression*, **2011**, 21, 291-301	1.3	10
89	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. *Aging*, **2011**, 3, 192-222	5.6	437
88	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. *Oncotarget*, **2011**, 2, 135-64	3.3	456
87	Hypoxia-induced down-modulation of PKCepsilon promotes trail-mediated apoptosis of tumor cells. *International Journal of Oncology*, **2010**, 37, 719-29	4.4	8
86	Reply to F. Damm et al. *Journal of Clinical Oncology*, **2010**, 28, e388-e389	2.2	1
85	eEF1A phosphorylation in the nucleus of insulin-stimulated C2C12 myoblasts: Ser is a novel substrate for protein kinase C *Molecular and Cellular Proteomics*, **2010**, 9, 2719-28	7.6	21
84	Mass spectrometry-based identification of Y745 of Vav1 as a tyrosine residue crucial in maturation of acute promyelocytic leukemia-derived cells. *Journal of Proteome Research*, **2010**, 9, 752-60	5.6	8
83	Inositide signaling in the nucleus: from physiology to pathology. *Advances in Enzyme Regulation*, **2010**, 50, 2-11		16
82	A role for PKCepsilon during C2C12 myogenic differentiation. *Cellular Signalling*, **2010**, 22, 629-35	4.9	14
81	Nuclear inositide signaling in myelodysplastic syndromes. *Journal of Cellular Biochemistry*, **2010**, 109, 1065-71	4.7	22
80	A role for PKR in hematologic malignancies. *Journal of Cellular Physiology*, **2010**, 223, 572-91	7	17
79	Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment. *Blood*, **2010**, 116, 233-233	2.2	1
78	Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study. *Blood*, **2010**, 116, 4029-4029	2.2	1
77	Phosphoinositide-specific phospholipase C beta1 signal transduction in the nucleus. *Methods in Molecular Biology*, **2010**, 645, 143-64	1.4	0
76	Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 16811-6	11.5	88
75	Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. *Journal of Clinical Oncology*, **2009**, 27, 782-90	2.2	52
74	Involvement of nuclear PLCbeta1 in lamin B1 phosphorylation and G2/M cell cycle progression. *FASEB Journal*, **2009**, 23, 957-66	0.9	58
73	Nuclear PLCbeta1 is required for 3T3-L1 adipocyte differentiation and regulates expression of the cyclin D3-cdk4 complex. *Cellular Signalling*, **2009**, 21, 926-35	4.9	38

72	PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation. *Journal of Cellular Physiology*, **2009**, 221, 232-41	7	26
71	Toxicity of antimony trioxide nanoparticles on human hematopoietic progenitor cells and comparison to cell lines. *Toxicology*, **2009**, 262, 121-9	4.4	85
70	Nuclear inositides: PI-PLC signaling in cell growth, differentiation and pathology. *Advances in Enzyme Regulation*, **2009**, 49, 2-10		39
69	Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients.. *Blood*, **2009**, 114, 2384-2384	2.2	
68	Catalytic activity of nuclear PLC-beta(1) is required for its signalling function during C2C12 differentiation. *Cellular Signalling*, **2008**, 20, 2013-21	4.9	36
67	Lamin A Ser404 is a nuclear target of Akt phosphorylation in C2C12 cells. *Journal of Proteome Research*, **2008**, 7, 4727-35	5.6	64
66	Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. *Cancer Research*, **2008**, 68, 9394-403	10.1	76
65	Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia. *Molecular Pharmacology*, **2008**, 74, 884-95	4.3	31
64	Inositide signaling: Nuclear targets and involvement in myelodysplastic syndromes. *Advances in Enzyme Regulation*, **2008**, 48, 2-9		7
63	Nuclear phospholipase C beta1 and cellular differentiation. *Frontiers in Bioscience - Landmark*, **2008**, 13, 2452-63	2.8	27
62	Multiple roles of phosphoinositide-specific phospholipase C isozymes. *BMB Reports*, **2008**, 41, 415-34	5.5	357
61	Expression of phosphoinositide-specific phospholipase C isoenzymes in cultured astrocytes. *Journal of Cellular Biochemistry*, **2007**, 100, 952-9	4.7	26
60	Nuclear inositide signaling: an appraisal of phospholipase C beta 1 behavior in myelodysplastic and leukemia cells. *Advances in Enzyme Regulation*, **2007**, 47, 2-9		8
59	NK cells and cancer. *Journal of Immunology*, **2007**, 178, 4011-6	5.3	198
58	The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. *Cancer Research*, **2007**, 67, 4287-94	10.1	75
57	Nuclear diacylglycerol kinase-zeta is a negative regulator of cell cycle progression in C2C12 mouse myoblasts. *FASEB Journal*, **2007**, 21, 3297-307	0.9	40
56	Inositide-dependent phospholipase C signaling mimics insulin in skeletal muscle differentiation by affecting specific regions of the cyclin D3 promoter. *Endocrinology*, **2007**, 148, 1108-17	4.8	49
55	Role of nuclear PLC and PI3K signaling in the development of cancer. *Future Lipidology*, **2007**, 2, 303-311		2

54	The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML). *Current Signal Transduction Therapy*, **2007**, 2, 246-256	0.8	2
53	Intranuclear 3Rphosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis?. *Cellular Signalling*, **2006**, 18, 1101-7	4.9	112
52	Caspase-dependent cleavage of 170-kDa P-glycoprotein during apoptosis of human T-lymphoblastoid CEM cells. *Journal of Cellular Physiology*, **2006**, 207, 836-44	7	42
51	Phosphoinositide-specific phospholipase C (PI-PLC) beta1 and nuclear lipid-dependent signaling. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2006**, 1761, 509-21	5	34
50	PKCepsilon controls protection against TRAIL in erythroid progenitors. *Blood*, **2006**, 107, 508-13	2.2	48
49	Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins **2006**, 28, 127		5
48	Proteomic-based analysis of nuclear signaling: PLCbeta1 affects the expression of the splicing factor SRp20 in Friend erythroleukemia cells. *Proteomics*, **2006**, 6, 5725-34	4.8	28
47	Signal transduction within the nucleus: revisiting phosphoinositide inositide-specific phospholipase Cbeta1. *Advances in Enzyme Regulation*, **2006**, 46, 2-11		13
46	Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome. *International Journal of Molecular Medicine*, **2006**, 18, 267-71	4.4	23
45	Application of flow cytometry to molecular medicine: Detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukaemia blasts. *International Journal of Molecular Medicine*, **2005**, 16, 1041	4.4	1
44	Nuclear phospholipase C: involvement in signal transduction. *Progress in Lipid Research*, **2005**, 44, 185-206	14.3	51
43	Nuclear phospholipase C beta1, regulation of the cell cycle and progression of acute myeloid leukemia. *Advances in Enzyme Regulation*, **2005**, 45, 126-35		16
42	Nuclear inositol lipid metabolism: more than just second messenger generation?. *Journal of Cellular Biochemistry*, **2005**, 96, 285-92	4.7	30
41	Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells. *Journal of Cellular Physiology*, **2005**, 202, 623-34	7	52
40	Expression of signal transduction proteins during the differentiation of primary human erythroblasts. *Journal of Cellular Physiology*, **2005**, 202, 831-8	7	22
39	Nuclear phospholipase C beta1 (PLCbeta1) affects CD24 expression in murine erythroleukemia cells. *Journal of Biological Chemistry*, **2005**, 280, 24221-6	5.4	29
38	Nuclear phospholipase C signaling through type 1 IGF receptor and its involvement in cell growth and differentiation. *Anticancer Research*, **2005**, 25, 2039-41	2.3	24
37	Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. *Blood*, **2004**, 104, 2418-24	2.2	349

36	Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase **2004**, 25, 1599		2
35	Expression of HLA class I antigen and proteasome subunits LMP-2 and LMP-10 in primary vs. metastatic breast carcinoma lesions **2004**, 25, 1625		2
34	Novel 2Rsubstituted, 3Rdeoxy-phosphatidyl-myo-inositol analogues reduce drug resistance in human leukaemia cell lines with an activated phosphoinositide 3-kinase/Akt pathway. *British Journal of Haematology*, **2004**, 126, 574-82	4.5	18
33	Nuclear inositides: facts and perspectives **2004**, 101, 47-64		66
32	Nuclear diacylglycerol kinase-theta is activated in response to nerve growth factor stimulation of PC12 cells. *Cellular Signalling*, **2004**, 16, 1263-71	4.9	17
31	Significance of subnuclear localization of key players of inositol lipid cycle. *Advances in Enzyme Regulation*, **2004**, 44, 51-60		21
30	Expression of phospholipase C beta family isoenzymes in C2C12 myoblasts during terminal differentiation. *Journal of Cellular Physiology*, **2004**, 200, 291-6	7	39
29	Up-regulation of nuclear PLCbeta1 in myogenic differentiation. *Journal of Cellular Physiology*, **2003**, 195, 446-52	7	55
28	Cbl competitively inhibits epidermal growth factor-induced activation of phospholipase C-gamma1. *Molecules and Cells*, **2003**, 15, 245-55	3.5	13
27	Inositides in the nucleus: regulation of nuclear PI-PLCbeta1. *Advances in Enzyme Regulation*, **2002**, 42, 181-93		23
26	Nuclear PLCbeta(1) acts as a negative regulator of p45/NF-E2 expression levels in Friend erythroleukemia cells. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2002**, 1589, 305-10	4.9	35
25	Role of CREB transcription factor in c-fos activation in natural killer cells. *European Journal of Immunology*, **2002**, 32, 3358-65	6.1	27
24	Molecular characterization of protein kinase C-alpha binding to lamin A. *Journal of Cellular Biochemistry*, **2002**, 86, 320-30	4.7	39
23	Noradrenergic and cholinergic innervation of the bone marrow. *International Journal of Molecular Medicine*, **2002**, 10, 77	4.4	8
22	Molecular characterization of the human PLC beta1 gene. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2002**, 1584, 46-54	5	18
21	Interleukin 2 activates nuclear phospholipase Cbeta by mitogen-activated protein kinase-dependent phosphorylation in human natural killer cells. *FASEB Journal*, **2001**, 15, 1789-91	0.9	33
20	Phosphorylation of nuclear phospholipase C beta1 by extracellular signal-regulated kinase mediates the mitogenic action of insulin-like growth factor I. *Molecular and Cellular Biology*, **2001**, 21, 2981-90	4.8	96
19	Nuclear inositol lipid signaling. *Advances in Enzyme Regulation*, **2001**, 41, 361-84		23

18	Nuclear phospholipase C and signaling. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2001**, 1530, 1-14	5	79
17	A role for nuclear phospholipase Cbeta 1 in cell cycle control. *Journal of Biological Chemistry*, **2000**, 275, 30520-4	5.4	124
16	Identification and chromosomal localisation by fluorescence in situ hybridisation of human gene of phosphoinositide-specific phospholipase C beta(1). *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2000**, 1484, 175-82	5	27
15	Inositides and the nucleus: phospholipase Cbeta family localization and signaling activity. *Advances in Enzyme Regulation*, **2000**, 40, 83-95		5
14	Insulin-like growth factor-I-dependent stimulation of nuclear phospholipase C-beta1 activity in Swiss 3T3 cells requires an intact cytoskeleton and is paralleled by increased phosphorylation of the phospholipase. *Journal of Cellular Biochemistry*, **1999**, 72, 339-48	4.7	28
13	Inositides in the nucleus: presence and characterisation of the isozymes of phospholipase beta family in NIH 3T3 cells. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **1999**, 1438, 295-9	5	31
12	Inositides in the nucleus: taking stock of PLC beta 1. *Advances in Enzyme Regulation*, **1998**, 38, 351-63		15
11	Phosphoinositide signalling in nuclei of Friend cells: DMSO-induced differentiation reduces the association of phosphatidylinositol-transfer protein with the nucleus. *Biochemical and Biophysical Research Communications*, **1997**, 230, 302-5	3.4	28
10	Nuclear lipid-dependent signal transduction in human osteosarcoma cells. *Advances in Enzyme Regulation*, **1997**, 37, 351-75		15
9	Inositol lipid cycle and autonomous nuclear signalling. *Advances in Enzyme Regulation*, **1996**, 36, 101-14		24
8	Inositides in nuclei of Friend cells: changes of polyphosphoinositide and diacylglycerol levels accompany cell differentiation. *Cellular Signalling*, **1995**, 7, 53-6	4.9	26
7	Nuclear inositol lipid cycle and differentiation. *Advances in Enzyme Regulation*, **1995**, 35, 23-33		9
6	Inositol lipid cycle in the nucleus. *Cellular Signalling*, **1994**, 6, 481-5	4.9	47
5	Nuclear localization and signalling activity of phosphoinositidase C beta in Swiss 3T3 cells. *Nature*, **1992**, 358, 242-5	50.4	300
4	Changes in nuclear inositol phospholipids induced in intact cells by insulin-like growth factor I. *Biochemical and Biophysical Research Communications*, **1989**, 159, 720-5	3.4	96
3	Rapid changes in phospholipid metabolism in the nuclei of Swiss 3T3 cells induced by treatment of the cells with insulin-like growth factor I. *Biochemical and Biophysical Research Communications*, **1988**, 154, 1266-72	3.4	90
2	Effect of phospholipids on transcription and ribonucleoprotein processing in isolated nuclei. *Advances in Enzyme Regulation*, **1986**, 25, 425-38		26
1	Conformational changes of nuclear chromatin related to phospholipid induced modifications of the template availability. *Advances in Enzyme Regulation*, **1984**, 22, 447-64		33